Security Notice: Please be aware of impersonation attempts using our company name
Legitimate communications from Ascent Research will only come from official @ascentresearch.com email addresses.
Quick Order Cart

Cat. No. ARG37153

ACOT8 Knockout Hela Polyclonal Cells

  • Product Type:

    Polyclonal Cell Population

  • Species:

    Homo sapiens (Human)

  • Tissue Source:

    Uterus (cervix)

  • Disease:

    Adenocarcinoma

The ACOT8 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout population derived from HeLa cells, featuring targeted disruption of the ACOT8 gene. This loss-of-function model impairs acyl-CoA thioesterase 8 activity, disrupting intracellular fatty acyl-CoA hydrolysis and altering free fatty acid and CoA pools. ACOT8 is regulated by PPAR?? and SREBP1c and interacts with peroxisomal import proteins PEX5 and PEX7. This model enables studies of lipid metabolism, peroxisomal beta-oxidation, and cancer cell proliferation, making it ideal for metabolic research and drug discovery targeting lipid pathways.

Inquire Now

In stock

Ships next business day


Ask a Question

Shipping Info:

Cryopreserved in vials and shipped on dry ice


Disclaimer:

For Research Use Only

  • Characteristics

    Host Cell

    HeLa

    Sex of Donor

    Female

    Age

    31 years

    Gene Name

    ACOT8

    Gene Identifier

    NCBI Gene ID 10005

    Morphology

    Epithelial-like

    Growth Mode

    Adherent

    Storage

    Liquid nitrogen (LN2)

  • Culture Conditions

    Growth medium

    MEM (with NEAA)

    Supplement(s)

    10% Fetal Bovine Serum, 1% Penicillin-Streptomycin Solution

    Temperature

    37°C

    Atmosphere

    5% CO₂

  • Quality Control

    Sterility testing

    The bacterial, yeast, and fungi are not detected in these cells by daily monitor.

    Mycoplasma testing

    Negative for mycoplasma through PCR analysis

  • Disclaimer

    Intended Use

    This product is intended for laboratory in vitro use only. lt is not intended for diagnostic, therapeutic, or clinical applications.

    Disclaimer

    Ascent Research endeavors to provide accurate and up-to-date product information. However, no warranties or representations are made regarding its completeness or reliability. References to scientific literature and patents are for informational purposes only, and the customer assumes sole responsibility for verifying their accuracy.

    By accepting this product, the customer acknowledges and agrees to assume all risks associated with its receipt, handling, storage, disposal, and use, including compliance with all applicable safety and environmental regulations and precautions. Relevant laws, regulations, and ethical guidelines must be followed in conducting any research, modifications, or derivatives derived from this product.

    This product is provided "AS IS", and except as expressly stated herein, Ascent Research disclaims all other warranties, express or implied. Under no circumstances shall Ascent Research, its affiliates, or representatives be liable for indirect, incidental, consequential, or punitive damages arising from the use of this material. While Ascent Research employs rigorous quality control measures, we shall not be held responsible for damages resulting from misidentification or misinterpretation of the provided materials.

Description

The ACOT8 Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal knockout cell population engineered to disrupt the ACOT8 gene in the HeLa human cervical carcinoma cell line. This loss-of-function model supports detailed investigations into acyl-CoA thioesterase 8, an enzyme critical for intracellular fatty acyl-CoA hydrolysis. The polyclonal format offers a heterogeneous knockout pool, minimizing clonal selection artifacts and enabling robust, reproducible phenotypic analyses. Researchers can systematically evaluate the consequences of ACOT8 disruption on lipid metabolism in a widely used epithelial cancer model.

HeLa cells, derived from a cervical adenocarcinoma, are immortalized by HPV18-mediated inactivation of p53 and retinoblastoma protein. This oncogenic transformation grants rapid proliferation, aneuploidy, and a pronounced capacity for lipid metabolic reprogramming. As a well-characterized model in cancer biology, HeLa provides an excellent platform for dissecting gene functions linked to peroxisomal biology, lipid signaling, and metabolic rewiring. The host??s extensive molecular toolkit and existing datasets further enhance its utility for CRISPR-based knockout studies.

ACOT8 encodes a peroxisomal and cytosolic thioesterase that hydrolyzes medium- to long-chain fatty acyl-CoAs into free fatty acids and CoA. ACOT8 expression is upregulated by PPAR?? and SREBP1c and is modulated by insulin and fatty acid levels. The released CoA contributes to acetyl-CoA and malonyl-CoA pools, influencing mitochondrial and peroxisomal beta-oxidation as well as lipid synthesis. ACOT8 interacts with peroxisomal import receptors PEX5 and PEX7 and acyl-CoA binding proteins. In the metabolic network, ACOT8 cooperates with enzymes such as ACOX1 and CPT1A to govern fatty acid flux and energy balance.

Knockout of ACOT8 in HeLa cells disrupts the acyl-CoA/free fatty acid equilibrium, providing a system to probe lipid metabolic vulnerabilities in cancer. The HeLa background??s high proliferation rate places unique demands on lipid supply and CoA recycling; ACOT8 loss may uncover dependencies in peroxisomal beta-oxidation and membrane biogenesis. This model is particularly suited to explore how altered acyl-CoA thioesterase activity affects lipid droplet dynamics and oncogenic signaling. It enables dissection of ACOT8-dependent pathways in an HPV-transformed, aneuploid context.

Applications include LC-MS-based fatty acid profiling, CoA quantification, beta-oxidation flux assays, and lipid droplet staining. Proliferation assays (MTS/MTT) and metabolic tracing with labeled fatty acids reveal the impact on cell growth and energy metabolism. The polyclonal format is ideal for pooled genetic screens and dose-response drug studies targeting lipid metabolism. For further technical details or to place an order, please contact Ascent Research.

Reset Password

    Reach Us Questions? Click Me Here!

    Fill out the form below and a member of our team will contact you shortly!

    *Required field



      Reach Us

      Fill out the form below and a member of our team will contact you shortly!

      *Required field

      Product Inquiry (Optional)